Janssen

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated E_DEPRECATED Error in file �functions_general.php� at line 333: trim(): Passing null to parameter #1 ($string) of type string is deprecated

E_DEPRECATED Error in file �functions_general.php� at line 186: Function utf8_encode() is deprecated

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. The legal entity for Janssen in the UK and Ireland is Janssen-Cilag Ltd.

Keywords:

Date	News
2020-02-14	New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Dis...
2020-02-11	Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a...
2020-02-10	Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Rel...
2020-02-03	Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
2020-01-23	The European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Paediatric Patien...
2020-01-10	Janssen Expands Research & Development Presence with Major Investment in South San Francisco
2019-12-30	Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
2019-12-21	Complete Response Letter Issued from U.S. FDA for Investigational Long-Acting HIV Regimen
2019-12-20	Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
2019-11-16	Janssen Leverages Wearable Technology to Reimagine Clinical Trial Design

Date

News

2020-02-14

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Dis...

2020-02-11

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a...

2020-02-10

Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Rel...

2020-02-03

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU

2020-01-23

The European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Paediatric Patien...